Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00070148 · ClinicalTrials.gov registry record · Phase 3
Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 155
- Enrollment target
NCT00070148 is a Phase 3 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 155 participants.
The verdict
NCT00070148, a Phase 3 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 155 participants
- Enrollment target
Study Summary
RATIONALE: Oxandrolone and megestrol may help prevent weight loss and improve quality of life in patients with cancer. It is not yet known whether oxandrolone is more effective than megestrol in preventing weight loss and improving quality of life in patients who are receiving chemotherapy for solid tumors. PURPOSE: This randomized phase III trial is studying oxandrolone to see how well it works compared to megestrol in preventing weight loss and improving quality of life in patients who are receiving chemotherapy for solid tumors.
Interventions
- DRUG Megestrol Acetate
- DRUG Oxandrolone 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2004-03-01 |
| Est. Completion | 2007-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00070148
The ClinicalTrials.gov registry entry for NCT00070148 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Megestrol Acetate is the first listed.
NCT00070148 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00070148 about?
NCT00070148 is a clinical study titled "Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer". RATIONALE: Oxandrolone and megestrol may help prevent weight loss and improve quality of life in patients with cancer. It is not yet known whether oxandrolone is more effective than megestrol in preventing weight loss and improving quality of life in patients who are receiving chemotherapy for solid...
What is the current status of trial NCT00070148?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 155 participants. The study started on 2004-03-01. Estimated completion is 2007-08-01.
What interventions are being tested in trial NCT00070148?
The interventions under investigation include: Megestrol Acetate (DRUG), Oxandrolone 20 mg (DRUG).
Who is sponsoring clinical trial NCT00070148?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.